SAB Biotherapeutics

SAB Biotherapeutics is a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D).

Country

United States
Loading